Head to Head Analysis: Guided Therapeutics (GTHP) and The Competition

Guided Therapeutics (OTCMKTS:GTHP) is one of 70 public companies in the “Electromedical equipment” industry, but how does it contrast to its peers? We will compare Guided Therapeutics to similar businesses based on the strength of its institutional ownership, valuation, profitability, dividends, earnings, risk and analyst recommendations.

Volatility & Risk

Guided Therapeutics has a beta of 0.52, meaning that its share price is 48% less volatile than the S&P 500. Comparatively, Guided Therapeutics’ peers have a beta of 18.38, meaning that their average share price is 1,738% more volatile than the S&P 500.

Profitability

This table compares Guided Therapeutics and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Guided Therapeutics	N/A	N/A	-138.23%
Guided Therapeutics Competitors	-350.61%	-97.06%	-31.48%

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Guided Therapeutics and its peers, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Guided Therapeutics	0	0	0	0	N/A
Guided Therapeutics Competitors	259	780	1923	59	2.59

As a group, “Electromedical equipment” companies have a potential upside of 3,172.71%. Given Guided Therapeutics’ peers higher probable upside, analysts plainly believe Guided Therapeutics has less favorable growth aspects than its peers.

Insider & Institutional Ownership

9.7% of Guided Therapeutics shares are owned by institutional investors. Comparatively, 44.2% of shares of all “Electromedical equipment” companies are owned by institutional investors. 66.8% of Guided Therapeutics shares are owned by insiders. Comparatively, 13.6% of shares of all “Electromedical equipment” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Guided Therapeutics and its peers gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Guided Therapeutics	$100,000.00	-$3.49 million	-5.35
Guided Therapeutics Competitors	$1.06 billion	$91.09 million	84.44

Guided Therapeutics’ peers have higher revenue and earnings than Guided Therapeutics. Guided Therapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Summary

Guided Therapeutics peers beat Guided Therapeutics on 6 of the 9 factors compared.

Guided Therapeutics Company Profile

Guided Therapeutics, Inc., a medical technology company, focuses on developing medical devices. It focuses on the commercialization of LuViva, a non-invasive cervical cancer detection device that identifies cervical cancers and precancers painlessly, non-invasively, and at the point-of-care by scanning the cervix with light, then analyzing the light reflected and fluorescent light. The company was formerly known as SpectRx, Inc. and changed its name to Guided Therapeutics, Inc. in February 2008. Guided Therapeutics, Inc. was incorporated in 1992 and is based in Norcross, Georgia.